Specify a stock or a cryptocurrency in the search bar to get a summary
Co-Diagnostics Inc
CODXCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109
Analytics
WallStreet Target Price
1.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CODX
Dividend Analytics CODX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CODX
Stock Valuation CODX
Financials CODX
Results | 2019 | Dynamics |